Arca
Skip to content
Tools
Tools

Glaucoma

Drug research and approvals for glaucoma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 18, 2026, 186 studies of glaucoma are recruiting on ClinicalTrials.gov, Health Canada has authorized 18 drug trials for it since 2013, FDA has 1 approved and 5 open orphan designations naming it, and the EU has 11 authorised medicines for it.

  • Recruiting worldwide: 186
  • Trials authorized in Canada: 18
  • FDA orphan approvals: 1
  • EU medicines: 11

Recruiting now

Newest start dates first, of 186 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 24 of 32

Phase 3 12 of 14

Phase 2 11

Phase 1 or earlier 12 of 13

How its trials ended

1,741 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 320 whose ending is known, 48% met their primary endpoint, 1% missed it and 51% stopped early.

  • Completed, result not reported90652%
  • Status unknown30217%
  • Ongoing21312%
  • Met its primary endpoint1539%
  • Stopped: other or unclear945%
  • Stopped: enrollment or feasibility352%
  • Stopped: sponsor or business decision221%
  • Stopped: lack of efficacy50%
  • Missed its primary endpoint40%
  • Stopped: funding40%
  • Stopped: safety30%

Trials authorized in Canada

The 10 newest of 18; search them all in Canada trials
Jul 10, 2026Clinical trial protocol title: a phase 1/2 study of REGN22530 in participants with primary open angle glaucoma or ocular hypertensionREGN22530RegeneronOngoing
May 11, 2026A multicenter, compassionate adaptive clinical study evaluating the safety and performance of the migs silicone implant for intraocular pressure reduction in…MitomycinHexiris Inc.Pending
Mar 5, 2026A multicenter, first-in-human adaptive clinical study evaluating the safety and performance of the migs silicone implant for intraocular pressure reduction in…MitomycinHexiris Inc.Pending
Jan 29, 2026Prospective, multicenter study of the preserflo microshunt in subjects with primary open-angle glaucoma who have failed previous medical and surgical treatmentMitomycinGlaukosOngoing
Nov 10, 2025A multicenter, first-in-human clinical study evaluating the safety and performance of the mist device for intraocular pressure reduction in patients with…MitomycinHexiris Inc.Ongoing
Dec 23, 2024Comparative efficacy of nsaid and steroid-nsaid combination following selective laser trabeculoplasty: a phase 3 single-centre randomized controlled trialKetorolac tromethamine/fluorometholoneThe Research Insititute of St. Joseph's HamiltonPending
Dec 20, 2022Safety of insulin eye drops in the treatment of open-angle glaucomaHuman recombinant insulinSanté Québec- Centre Hospitalier De L’université De MontréalPending
May 10, 2022Efficacy and safety assessment of T4032 (unpreserved bimatoprost 0.01%) versus lumigan® 0.01% in ocular hypertensive or glaucomatous patientsBimatoprost (T4032)Laboratoires TheaClosed
Oct 21, 2019An investigator-initiated multi-center prospective clinical trial to examine the efficacy of peri-operative nsaid vs steroid treatment in trabeculectomy wound…BromfenacLawson Health Research InstitutePending
Mar 22, 2019An extension trial to evaluate the long-term safety and efficacy of bimatoprost sr in patients with open angle glaucoma or ocular hypertensionBimatoprostAbbVieClosed

FDA orphan designations

Approved first, then open designations, newest first
Feb 7, 2012MitosolAn adjunct to ab externo glaucoma surgery.Glaukos CorporationApproved
Jun 4, 2015Synthetic 14-mer phosphorothioate antisense oligonucleotide…Prevention of scarring post glaucoma filtration surgeryIsarna Therapeutics GmbHDesignated
Mar 24, 20154-(4-Methoxy-phenylamino)-6-methylcarbamyl-quinoline-3-carbo…Prevention of scarring post ab externo glaucoma surgeryClanotech ABDesignated
Dec 23, 2010TranilastPrevention of scarring following glaucoma filtration surgeryEsperante Development B.V.Designated
Aug 20, 1993Mitomycin-CTreatment of refractory glaucoma as an adjunct to ab externo glaucoma surgery.IOP Inc.Designated
Nov 16, 1987Thymoxamine HClReversal of phenylephrine-induced mydriasis in patients who have narrow anterior angles and are at risk of developing an acute attack of…Iolab PharmaceuticalsDesignated

Medicines authorised in the EU

Newest first
Nov 15, 2023CatiolanzeLatanoprostSanten OyEMA ↗
Jan 7, 2021RoclandaLatanoprost / netarsudilSanten OyEMA ↗
Nov 19, 2019RhokiinsaNetarsudilSanten OyEMA ↗
Jul 18, 2014SimbrinzaBrinzolamide; brimonidine tartrateNovartis Europharm LimitedEMA ↗
Feb 20, 2014IzbaTravoprostNovartis Europharm LimitedEMA ↗
Nov 25, 2008AzargaBrinzolamide; timololNovartis Europharm LimitedEMA ↗
May 19, 2006GanfortBimatoprost; timololAbbVie Deutschland GmbH & Co. KGEMA ↗
Apr 23, 2006DuoTravTravoprost; timololNovartis Europharm LimitedEMA ↗
Mar 8, 2002LumiganBimatoprostAbbVie Deutschland GmbH & Co. KGEMA ↗
Nov 27, 2001TravatanTravoprostNovartis Europharm LimitedEMA ↗
Mar 9, 2000AzoptBrinzolamideNovartis Europharm LimitedEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.